Journal Summary - Discover more summaries and articles from M3 India

Journal Summaries

Oncology

Pharmacology/Therapy

Randomized phase 3 postoperative trial of platinum-based chemotherapy vs capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131

Journal of Clinical Oncology | Jun 10, 2021 Pharmacology/Therapy

Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada

Gynecologic Oncology | Jun 10, 2021 Pharmacology/Therapy

A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer

BMC Cancer | Jun 10, 2021 Pharmacology/Therapy

Clinical effect of radiotherapy combined with capecitabine after neoadjuvant therapy for rectal cancer

Journal of Oncology | Jun 10, 2021 Pharmacology/Therapy

PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer

Cancer Medicine | Jun 10, 2021 Pharmacology/Therapy

Adjuvant nivolumab vs placebo in muscle-invasive urothelial carcinoma

New England Journal of Medicine | Jun 09, 2021 Pharmacology/Therapy

Sotorasib for lung cancers with KRAS p.G12C mutation

New England Journal of Medicine | Jun 09, 2021 Pharmacology/Therapy

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial

The Lancet | Jun 09, 2021 Pharmacology/Therapy

First-line nivolumab plus chemotherapy vs chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial

The Lancet | Jun 09, 2021 Pharmacology/Therapy

Pembrolizumab and lenvatinib vs carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis

Gynecologic Oncology | Jun 09, 2021 Pharmacology/Therapy

« Prev 1 … 35 36 37 38 39 … 375 Next »

Randomized phase 3 postoperative trial of platinum-based chemotherapy vs capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131

Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada

A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer

Clinical effect of radiotherapy combined with capecitabine after neoadjuvant therapy for rectal cancer

PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer

Adjuvant nivolumab vs placebo in muscle-invasive urothelial carcinoma

Sotorasib for lung cancers with KRAS p.G12C mutation

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial

First-line nivolumab plus chemotherapy vs chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial

Pembrolizumab and lenvatinib vs carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis

MD Clip on Recent Advances in Lipid Management with Dr Gopinath

Article: Anti-Inflammatory Diets for Pain and Arthritis Management

Many young adults have high long-term risk for cardiovascular disease, study finds

Article on Hypertension in CKD Patients: Management Updates

New research aims to transform treatments of aggressive blood cancer

Randomized phase 3 postoperative trial of platinum-based chemotherapy vs capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131

Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada

A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer

Clinical effect of radiotherapy combined with capecitabine after neoadjuvant therapy for rectal cancer

PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer

Adjuvant nivolumab vs placebo in muscle-invasive urothelial carcinoma

Sotorasib for lung cancers with KRAS p.G12C mutation

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial

First-line nivolumab plus chemotherapy vs chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial

Pembrolizumab and lenvatinib vs carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis

MD Clip on Recent Advances in Lipid Management with Dr Gopinath

Article: Anti-Inflammatory Diets for Pain and Arthritis Management

Many young adults have high long-term risk for cardiovascular disease, study finds

Article on Hypertension in CKD Patients: Management Updates

New research aims to transform treatments of aggressive blood cancer

Select Specialty

Select Topic